These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 22507895)
61. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298 [TBL] [Abstract][Full Text] [Related]
62. Risk factors for multidrug-resistant tuberculosis in Hong Kong. Law WS; Yew WW; Chiu Leung C; Kam KM; Tam CM; Chan CK; Leung CC Int J Tuberc Lung Dis; 2008 Sep; 12(9):1065-70. PubMed ID: 18713506 [TBL] [Abstract][Full Text] [Related]
63. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China. Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894 [TBL] [Abstract][Full Text] [Related]
64. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497 [TBL] [Abstract][Full Text] [Related]
65. Outcome of community-initiated treatment of drug-resistant tuberculosis patients in Lagos, Nigeria. Bakare AM; Udunze OC; Bamidele JO; Omoniyi A; Osman E; Daniel OJ Trans R Soc Trop Med Hyg; 2021 Sep; 115(9):1061-1065. PubMed ID: 33427297 [TBL] [Abstract][Full Text] [Related]
66. Multidrug-resistant tuberculosis in the United States, 2011-2016: patient characteristics and risk factors. Chen MP; Miramontes R; Kammerer JS Int J Tuberc Lung Dis; 2020 Jan; 24(1):92-99. PubMed ID: 32005311 [TBL] [Abstract][Full Text] [Related]
67. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117 [TBL] [Abstract][Full Text] [Related]
68. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients. Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643 [TBL] [Abstract][Full Text] [Related]
69. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. Satti H; McLaughlin MM; Omotayo DB; Keshavjee S; Becerra MC; Mukherjee JS; Seung KJ PLoS One; 2012; 7(5):e37114. PubMed ID: 22629356 [TBL] [Abstract][Full Text] [Related]
70. Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study. Alene KA; Viney K; McBryde ES; Gray DJ; Melku M; Clements ACA Transbound Emerg Dis; 2019 Jul; 66(4):1611-1618. PubMed ID: 30924283 [TBL] [Abstract][Full Text] [Related]
71. High frequency of azole resistant Candida spp. colonization among presumptive multidrug resistant tuberculosis (MDR-TB) patients. Darma S; Ambara A; Aman AT; Annisa L; Nurrokhman ; Nuryastuti T; Wibawa T PLoS One; 2020; 15(11):e0242542. PubMed ID: 33212470 [TBL] [Abstract][Full Text] [Related]
72. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Palacios E; Franke M; Muñoz M; Hurtado R; Dallman R; Chalco K; Guerra D; Mestanza L; Llaro K; Bonilla C; Sebastian J; Bayona J; Lygizos M; Anger H; Shin S Int J Tuberc Lung Dis; 2012; 16(3):348-54. PubMed ID: 22640448 [TBL] [Abstract][Full Text] [Related]
73. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Ali MH; Alrasheedy AA; Kibuule D; Godman B; Hassali MA; Ali HMH Expert Rev Anti Infect Ther; 2019 Nov; 17(11):927-937. PubMed ID: 31689134 [No Abstract] [Full Text] [Related]
74. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study. Kizito E; Musaazi J; Mutesasira K; Twinomugisha F; Namwanje H; Kiyemba T; Freitas Lopez DB; Nicholas NS; Nkolo A; Birabwa E; Dejene S; Zawedde-Muyanja S BMC Infect Dis; 2021 Mar; 21(1):292. PubMed ID: 33752637 [TBL] [Abstract][Full Text] [Related]
75. Multidrug-resistant tuberculosis in Western Australia, 1998-2012. Francis JR; Blyth CC; Colby S; Fagan JM; Waring J Med J Aust; 2014 Apr; 200(6):328-32. PubMed ID: 24702090 [TBL] [Abstract][Full Text] [Related]
76. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study. Chaves-Torres NM; Fadul S; Patiño J; Netto E PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619 [TBL] [Abstract][Full Text] [Related]
77. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. Chung-Delgado K; Guillen-Bravo S; Revilla-Montag A; Bernabe-Ortiz A PLoS One; 2015; 10(3):e0119332. PubMed ID: 25790076 [TBL] [Abstract][Full Text] [Related]
78. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Alene KA; Viney K; McBryde ES; Tsegaye AT; Clements AC Trop Med Int Health; 2017 Mar; 22(3):351-362. PubMed ID: 27978594 [TBL] [Abstract][Full Text] [Related]
79. Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana. Hafkin J; Modongo C; Newcomb C; Lowenthal E; MacGregor RR; Steenhoff AP; Friedman H; Bisson GP Int J Tuberc Lung Dis; 2013 Mar; 17(3):348-53. PubMed ID: 23321297 [TBL] [Abstract][Full Text] [Related]
80. High treatment success rate among multidrug-resistant tuberculosis patients in Myanmar, 2012-2014: a retrospective cohort study. Thu MK; Kumar AMV; Soe KT; Saw S; Thein S; Mynit Z; Maung HMW; Aung ST Trans R Soc Trop Med Hyg; 2017 Sep; 111(9):410-417. PubMed ID: 29351672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]